Fouladi DF, Zarghampour M, Pandey P, et al. - Among patients with hepatic colorectal metastases (CLMs), researchers analyzed the value of baseline 3D-ADC and anticipated short-term response to treatment. Liver MR images of 546 individuals with CLMs (2008–2015) have been reviewed retrospectively and 68 patients met the criteria for inclusion. In anticipating response to different treatments in hepatic CLMs, baseline 3D-ADC is a highly specific biomarker. The baseline ADC prediction rate is higher for ⁹⁰Y radioembolization than in hepatic CLMs for systemic chemotherapy/TACE. Findings revealed that 3D-ADC outperforms 2D-ADC in the estimation of short-term response to hepatic CLM therapy.